Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 395
  • Home
  • Print this page
  • Email this page


 
   Table of Contents      
LETTER TO THE EDITOR
Year : 2019  |  Volume : 67  |  Issue : 1  |  Page : 180

Comment on: Dramatic response to intravitreal bevacizumab in hypertensive retinopathy


1 Department of Vitreoretina and Uvea, ASG Eye Hospital, Dakshindari Road, VIP Road, Sreebhumi, Near Lake Town, West Bengal, India
2 Department of Internal Medicine and Intensive Care, Columbia Asia Hospital, Salt Lake City, Kolkata, West Bengal, India

Date of Web Publication21-Dec-2018

Correspondence Address:
Dr. Koushik Tripathy
Department of Vitreoretina and Uvea, ASG Eye Hospital, 403/1 Alcove Gloria, Dakshindari Road, VIP Road, Sreebhumi, Near Lake Town, Kolkata - 700 048, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijo.IJO_1654_18

Rights and Permissions

How to cite this article:
Tripathy K, Chaudhuri A. Comment on: Dramatic response to intravitreal bevacizumab in hypertensive retinopathy. Indian J Ophthalmol 2019;67:180

How to cite this URL:
Tripathy K, Chaudhuri A. Comment on: Dramatic response to intravitreal bevacizumab in hypertensive retinopathy. Indian J Ophthalmol [serial online] 2019 [cited 2019 Jan 19];67:180. Available from: http://www.ijo.in/text.asp?2019/67/1/180/248132



Sir,

We read with interest the case report[1] on the resolution of bilateral subfoveal fluid and disc edema due to hypertensive retinopathy (HTNR) after unilateral intravitreal bevacizumab. We want to discuss few points.

  1. As one eye did not receive the intravitreal injection, one could consider that eye as the control eye as opposed to the other interventional eye with intravitreal injection. Resolution of the control eye's subfoveal fluid after 1 month of the intervention may denote a positive effect of the control of blood pressure (BP) or systemic disease and may not solely be related to the contralateral effect of the injection as the authors have proposed. It would be interesting to know if the patient underwent any interventions to control BP including hemodialysis.
  2. Typically mean arterial BP (MABP) is calculated as diastolic BP + (systolic BP − diastolic BP)/3. Thus, the calculated MABP of 210/140 mm Hg would be 140 + (210 − 140)/3 = 163.3 mm Hg and not 136 mm Hg. Was MABP measured invasively by an arterial line?
  3. As the primary cause of HTNR is hypertension, the adequate control of hypertension is the most important intervention. Without the adequate control of BP, any intervention including intravitreal anti-vascular endothelial growth factor (VEGF) agents may not be considered. Though bevacizumab has been considered as a “wonder drug,” it carries a rare but devastating risk of blindness due to endophthalmitis.[2] However, in the clinical setting even after control of hypertension, the subfoveal fluid may not resolve and the patient may want earlier visual rehabilitation. Salman[3] used intravitreal bevacizumab in 12 cases of persistent HTNR despite control of hypertension for 1 month and noted stabilization and improvement of vision in all cases. This paper[1] also adds to the evidence[4],[5] that anti-VEGF agents may be helpful in HTNR. The exact role of anti-VEGF agents in HTNR needs further exploration, but these agents may add to the armamentarium to treat the cases of HTNR with subfoveal fluid which do not resolve despite good systemic control.


Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Padhy S, Kumar V. Dramatic response to intravitreal Bevacizumab in hypertensive retinopathy. Indian J Ophthalmol 2018;66:1494-5.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
Kumar A, Tripathy K, Chawla R. Intraocular use of bevacizumab in India: An issue resolved? Natl Med J India 2017;30:345-7.  Back to cited text no. 2
[PUBMED]  [Full text]  
3.
Salman AG. Intravitreal bevacizumab in persistent retinopathy secondary to malignant hypertension. Saudi J Ophthalmol 2013;27:25-9.  Back to cited text no. 3
    
4.
Kim EY, Lew HM, Song JH. Effect of intravitreal bevacizumab (Avastin(®)) therapy in malignant hypertensive retinopathy: A report of two cases. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther 2012;28:318-22.  Back to cited text no. 4
    
5.
Al-Halafi AM. Tremendous result of bevacizumab in malignant hypertensive retinopathy. Oman J Ophthalmol 2015;8:61-3.  Back to cited text no. 5
[PUBMED]  [Full text]  




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed121    
    Printed0    
    Emailed0    
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal